{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:02:04Z","timestamp":1772136124626,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NMRT France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic Ductal AdenoCarcinoma (PDAC) represents about 90% of pancreatic cancers. It is one of the most aggressive cancer, with a 5-year survival rate below 10% due to late diagnosis and poor therapeutic efficiency. This bad prognosis thus encourages intense research in order to better understand PDAC pathogenesis and molecular basis leading to the development of innovative therapeutic strategies. This research frequently involves the KC (LSL:\n                    <jats:italic>Kras<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>G12D<\/jats:italic>\n                    <\/jats:sup>\n                    ;\n                    <jats:italic>Pdx1<\/jats:italic>\n                    -CRE) genetically engineered mouse model, which leads to pancreatic cancer predisposition. However, as frequently encountered in animal models, the KC mouse model also exhibits biases. Herein, we report a new adverse effect of\n                    <jats:italic>Kras<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>G12D<\/jats:italic>\n                    <\/jats:sup>\n                    mutation in KC mouse model. In our hands, 10% of KC mice developed clinical signs reaching pre-defined end-points between 100- and 150-days post-parturition, and associated with large thymic mass development. Histological and genetic analyses of this massive thymus enabled us (1) to characterize it as a highly proliferative thymic lymphoma and (2) to detect the unexpected recombination of the Lox-STOP-Lox cassette upstream\n                    <jats:italic>Kras<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>G12D<\/jats:italic>\n                    <\/jats:sup>\n                    allele and subsequent KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    protein expression in all cells composing thymic masses. Finally, we highlighted that development of such thymic tumor was associated with accelerated pancreatic carcinogenesis, immune compartment disorganization, and in some cases, lung malignancies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-94566-x","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T06:03:49Z","timestamp":1627020229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of thymic tumor in [LSL:KrasG12D; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis"],"prefix":"10.1038","volume":"11","author":[{"given":"Sophie","family":"Liot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na\u00efma","family":"El Kholti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Balas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Genestier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Valcourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"94566_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"94566_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74, 2913\u20132921 (2014).","journal-title":"Cancer Res"},{"key":"94566_CR3","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/cam4.767","volume":"5","author":"AS Quante","year":"2016","unstructured":"Quante, A. S. et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 5, 2649\u20132656 (2016).","journal-title":"Cancer Med."},{"key":"94566_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol 10, 10\u201327 (2019).","journal-title":"World J Oncol"},{"key":"94566_CR5","doi-asserted-by":"publisher","unstructured":"Eibl, A. S. and G. Pancreatic Ductal Adenocarcinoma. Pancreapedia: The Exocrine Pancreas Knowledge Base (2015). https:\/\/doi.org\/10.3998\/panc.2015.14.","DOI":"10.3998\/panc.2015.14"},{"key":"94566_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2468-1253(16)30079-6","volume":"1","author":"FM Walter","year":"2016","unstructured":"Walter, F. M. et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): A prospective cohort study. Lancet Gastroenterol. Hepatol. 1, 298\u2013306 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"94566_CR7","doi-asserted-by":"crossref","unstructured":"Adamska, A., Domenichini, A. & Falasca, M. Pancreatic ductal adenocarcinoma: Current and evolving therapies. Int J Mol Sci 18, 1338 (2017).","DOI":"10.3390\/ijms18071338"},{"key":"94566_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharmthera.2017.02.013","volume":"173","author":"D Behrens","year":"2017","unstructured":"Behrens, D., Walther, W. & Fichtner, I. Pancreatic cancer models for translational research. Pharmacol. Ther. 173, 146\u2013158 (2017).","journal-title":"Pharmacol. Ther."},{"key":"94566_CR9","doi-asserted-by":"crossref","unstructured":"Krempley, B. D. & Yu, K. H. Preclinical models of pancreatic ductal adenocarcinoma. Chin. Clin. Oncol. 6, 25 (2017).","DOI":"10.21037\/cco.2017.06.15"},{"key":"94566_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MPA.0b013e3181c15619","volume":"39","author":"Y Ding","year":"2010","unstructured":"Ding, Y., Cravero, J. D., Adrian, K. & Grippo, P. Modeling pancreatic cancer in vivo: From xenograft and carcinogen-induced systems to genetically engineered mice. Pancreas 39, 283\u2013292 (2010).","journal-title":"Pancreas"},{"key":"94566_CR11","unstructured":"Bartholin, L. Pancreatic cancer and the tumor microenvironment: Mesenchyme\u2019s role in pancreatic carcinogenesis. In Pancreatic Cancer and Tumor Microenvironment (eds. Grippo, P. J. & Munshi, H. G.) Chapter 4 (Transworld Research Network, 2012)."},{"key":"94566_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5306\/wjco.v2.i5.195","volume":"2","author":"H Ijichi","year":"2011","unstructured":"Ijichi, H. Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. World J. Clin. Oncol. 2, 195\u2013202 (2011).","journal-title":"World J. Clin. Oncol."},{"key":"94566_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2012.03.002","volume":"142","author":"PA P\u00e9rez-Mancera","year":"2012","unstructured":"P\u00e9rez-Mancera, P. A., Guerra, C., Barbacid, M. & Tuveson, D. A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079\u20131092 (2012).","journal-title":"Gastroenterology"},{"key":"94566_CR14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/gutjnl-2011-300756","volume":"61","author":"PK Mazur","year":"2012","unstructured":"Mazur, P. K. & Siveke, J. T. Genetically engineered mouse models of pancreatic cancer: Unravelling tumour biology and progressing translational oncology. Gut 61, 1488\u20131500 (2012).","journal-title":"Gut"},{"key":"94566_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.7150\/jca.37529","volume":"11","author":"K Kong","year":"2020","unstructured":"Kong, K., Guo, M., Liu, Y. & Zheng, J. Progress in animal models of pancreatic ductal adenocarcinoma. J Cancer 11, 1555\u20131567 (2020).","journal-title":"J Cancer"},{"key":"94566_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1101\/gad.184701","volume":"15","author":"M Wagner","year":"2001","unstructured":"Wagner, M. et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 15, 286\u2013293 (2001).","journal-title":"Genes Dev."},{"key":"94566_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/0092-8674(90)90075-P","volume":"61","author":"EP Sandgren","year":"1990","unstructured":"Sandgren, E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L. & Lee, D. C. Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121\u20131135 (1990).","journal-title":"Cell"},{"key":"94566_CR18","doi-asserted-by":"publisher","first-page":"150960","DOI":"10.1155\/2010\/150960","volume":"2010","author":"S Jan\u010d\u00edk","year":"2010","unstructured":"Jan\u010d\u00edk, S., Dr\u00e1bek, J., Radzioch, D. & Hajd\u00fach, M. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol. 2010, 150960 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"94566_CR19","doi-asserted-by":"crossref","unstructured":"Weng, C.-C., Lin, Y.-C. & Cheng, K.-H. The use of genetically engineered mouse models for studying the function of mutated driver genes in pancreatic cancer. J Clin Med 8, 1369 (2019).","DOI":"10.3390\/jcm8091369"},{"key":"94566_CR20","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1042\/BCJ20190839","volume":"477","author":"WE Kattan","year":"2020","unstructured":"Kattan, W. E. & Hancock, J. F. RAS Function in cancer cells: Translating membrane biology and biochemistry into new therapeutics. Biochem. J. 477, 2893\u20132919 (2020).","journal-title":"Biochem. J."},{"key":"94566_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar, J. & Kashofer, K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 39, 1029\u20131038 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"94566_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153\u2013168 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"94566_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1947601911408080","volume":"2","author":"RC O\u2019Hagan","year":"2011","unstructured":"O\u2019Hagan, R. C. & Heyer, J. KRAS mouse models. Genes Cancer 2, 335\u2013343 (2011).","journal-title":"Genes Cancer"},{"key":"94566_CR24","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1101\/gad.943001","volume":"15","author":"EL Jackson","year":"2001","unstructured":"Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243\u20133248 (2001).","journal-title":"Genes Dev."},{"key":"94566_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437\u2013450 (2003).","journal-title":"Cancer Cell"},{"key":"94566_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"94566_CR27","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1101\/gad.1158703","volume":"17","author":"AJ Aguirre","year":"2003","unstructured":"Aguirre, A. J. et al. Activated Kras and Ink4a\/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112\u20133126 (2003).","journal-title":"Genes Dev."},{"key":"94566_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.molonc.2013.02.002","volume":"7","author":"C Guerra","year":"2013","unstructured":"Guerra, C. & Barbacid, M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol. Oncol. 7, 232\u2013247 (2013).","journal-title":"Mol. Oncol."},{"key":"94566_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00006676-200403000-00001","volume":"28","author":"S Ashizawa","year":"2004","unstructured":"Ashizawa, S., Brunicardi, F. C. & Wang, X.-P. PDX-1 and the pancreas. Pancreas 28, 109\u2013120 (2004).","journal-title":"Pancreas"},{"key":"94566_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1134\/S000629791708003X","volume":"82","author":"TV Vinogradova","year":"2017","unstructured":"Vinogradova, T. V. & Sverdlov, E. D. PDX1: A unique pancreatic master regulator constantly changes its functions during embryonic development and progression of pancreatic cancer. Biochemistry Moscow 82, 887\u2013893 (2017).","journal-title":"Biochemistry Moscow"},{"key":"94566_CR31","doi-asserted-by":"publisher","first-page":"18913","DOI":"10.1073\/pnas.0810097105","volume":"105","author":"N Habbe","year":"2008","unstructured":"Habbe, N. et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. U.S.A. 105, 18913\u201318918 (2008).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"94566_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1101\/sqb.2005.70.040","volume":"70","author":"DA Tuveson","year":"2005","unstructured":"Tuveson, D. A. & Hingorani, S. R. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 70, 65\u201372 (2005).","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"94566_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/PAI.0b013e318206d958","volume":"19","author":"JY Park","year":"2011","unstructured":"Park, J. Y. et al. Pdx1 expression in pancreatic precursor lesions and neoplasms. Appl. Immunohistochem. Mol. Morphol. 19, 444\u2013449 (2011).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"94566_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/CM9.0000000000000628","volume":"133","author":"Z-C Tang","year":"2020","unstructured":"Tang, Z.-C., Chu, Y., Tan, Y.-Y., Li, J. & Gao, S. Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus. Chin. Med. J. (Engl.) 133, 344\u2013350 (2020).","journal-title":"Chin. Med. J. (Engl.)"},{"key":"94566_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pan.2013.02.001","volume":"13","author":"J Gout","year":"2013","unstructured":"Gout, J. et al. The conditional expression of KRAS G12D in mouse pancreas induces disorganization of endocrine islets prior the onset of ductal pre-cancerous lesions. Pancreatology 13, 191\u2013195 (2013).","journal-title":"Pancreatology"},{"key":"94566_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccr.2009.09.027","volume":"16","author":"SYG Friedlander","year":"2009","unstructured":"Friedlander, S. Y. G. et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16, 379\u2013389 (2009).","journal-title":"Cancer Cell"},{"key":"94566_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.semtcvs.2004.12.002","volume":"17","author":"RP Hasserjian","year":"2005","unstructured":"Hasserjian, R. P., Str\u00f6bel, P. & Marx, A. Pathology of thymic tumors. Semin. Thorac. Cardiovasc. Surg. 17, 2\u201311 (2005).","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"94566_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/01926230600978458","volume":"34","author":"G Pearse","year":"2006","unstructured":"Pearse, G. Histopathology of the thymus. Toxicol Pathol 34, 515\u2013547 (2006).","journal-title":"Toxicol Pathol"},{"key":"94566_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2014.11.007","volume":"771","author":"X Huo","year":"2015","unstructured":"Huo, X. et al. Analysis of the relationship between microsatellite instability and thymic lymphoma induced by N-methyl-N-nitrosourea in C57BL\/6J mice. Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis 771, 21\u201328 (2015).","journal-title":"Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis"},{"key":"94566_CR40","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1101\/gad.252148.114","volume":"28","author":"C Dudgeon","year":"2014","unstructured":"Dudgeon, C. et al. The evolution of thymic lymphomas in p53 knockout mice. Genes Dev 28, 2613\u20132620 (2014).","journal-title":"Genes Dev"},{"key":"94566_CR41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/35074129","volume":"410","author":"L Johnson","year":"2001","unstructured":"Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111\u20131116 (2001).","journal-title":"Nature"},{"key":"94566_CR42","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.2337\/db10-0476","volume":"59","author":"S Noso","year":"2010","unstructured":"Noso, S. et al. Insulin transactivator MafA regulates intrathymic expression of insulin and affects susceptibility to type 1 diabetes. Diabetes 59, 2579\u20132587 (2010).","journal-title":"Diabetes"},{"key":"94566_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1006\/jaut.2002.0616","volume":"19","author":"MK Brimnes","year":"2002","unstructured":"Brimnes, M. K. et al. Low expression of insulin in the thymus of non-obese diabetic mice. J. Autoimmun. 19, 203\u2013213 (2002).","journal-title":"J. Autoimmun."},{"key":"94566_CR44","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1371\/journal.pone.0013578","volume":"5","author":"PK Mazur","year":"2010","unstructured":"Mazur, P. K. et al. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in Murine KrasG12D-induced skin carcinogenesis in vivo. PLOS ONE 5, 13578 (2010).","journal-title":"PLOS ONE"},{"key":"94566_CR45","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/S0092-8674(02)00675-X","volume":"109","author":"CH Bassing","year":"2002","unstructured":"Bassing, C. H., Swat, W. & Alt, F. W. The mechanism and regulation of chromosomal V(D)J recombination. Cell 109, S45\u2013S55 (2002).","journal-title":"Cell"},{"key":"94566_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/bies.950170210","volume":"17","author":"HL Klein","year":"1995","unstructured":"Klein, H. L. Genetic control of intrachromosomal recombination. BioEssays 17, 147\u2013159 (1995).","journal-title":"BioEssays"},{"key":"94566_CR47","doi-asserted-by":"publisher","first-page":"e1005098","DOI":"10.1371\/journal.pgen.1005098","volume":"11","author":"SL Andersen","year":"2015","unstructured":"Andersen, S. L., Sloan, R. S., Petes, T. D. & Jinks-Robertson, S. Genome-destabilizing effects associated with Top1 loss or accumulation of Top1 cleavage complexes in yeast. PLOS Genet. 11, e1005098 (2015).","journal-title":"PLOS Genet."},{"key":"94566_CR48","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1182\/blood-2008-03-147587","volume":"112","author":"T Kindler","year":"2008","unstructured":"Kindler, T. et al. K-RasG12D\u2013induced T-cell lymphoblastic lymphoma\/leukemias harbor Notch1 mutations and are sensitive to \u03b3-secretase inhibitors. Blood 112, 3373\u20133382 (2008).","journal-title":"Blood"},{"key":"94566_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.coi.2013.01.006","volume":"25","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide, R. H. & Bayne, L. J. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol. 25, 200\u2013205 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"94566_CR50","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1177\/0271678X20943823","volume":"40","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research*. J. Cereb. Blood Flow Metab. 40, 1769\u20131777 (2020).","journal-title":"J. Cereb. Blood Flow Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94566-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94566-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94566-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:36:37Z","timestamp":1670049397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94566-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94566"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94566-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-383266\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15075"}}